公开(公告)号：US20230405153A1

公开(公告)日：2023-12-21

申请号：US18336708

申请日：2023-06-16

Applicant: Purdue Research Foundation

Inventor： Philip Stewart Low ,  Ramesh Mukkamala ,  Madduri Srinivasarao

IPC: A61K49/08 ,  A61K49/10

CPC classification number: A61K49/085 ,  A61K49/108

Abstract: A conjugate comprising FL-L-IA, wherein FL is a radical of a small molecule ligand that specifically binds with fibroblast activation protein (FAP), L is a linker, which binds an FL to IA, and IA is a radical of a magnetic resonance imaging (MRI) agent, or a pharmaceutically acceptable salt thereof; a composition comprising same; and a method of using the conjugate or composition to image cells, a tissue, or an organ that express(es) FAP with magnetic resonance imaging.

公开(公告)号：US20230398238A1

公开(公告)日：2023-12-14

申请号：US18455407

申请日：2023-08-24

Applicant: Texas Children's Hospital ,  Alzeca Biosciences, LLC

Inventor： Eric A. Tanifum ,  Xianwei Sun ,  Ananth V. Annapragada ,  Carlo Medici

IPC: A61K49/08 ,  C07C49/755 ,  C07C65/40 ,  C07D333/22 ,  A61K49/18 ,  A61K47/54 ,  A61K9/127 ,  A61K49/10

CPC classification number: A61K49/085 ,  C07C49/755 ,  C07C65/40 ,  C07D333/22 ,  A61K49/1812 ,  A61K47/542 ,  A61K47/545 ,  A61K9/1271 ,  A61K49/108 ,  A61K47/544

Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I:




wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH═CH— or




A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230355810A1

公开(公告)日：2023-11-09

申请号：US18310588

申请日：2023-05-02

Applicant: B. Braun Melsungen AG

Inventor： Thorsten Keller ,  Doris Rothlein ,  Jurgen Schmitt ,  Thore Dietrich ,  Philipp Stawowy ,  Eckart Fleck

IPC: A61K49/18 ,  A61K49/10 ,  A61B5/055 ,  G01R33/56

CPC classification number: A61K49/1806 ,  A61K49/10 ,  A61B5/055 ,  G01R33/5601

Abstract: The present invention relates to an aqueous emulsion comprising



a) a semifluorinated compound of formula I:






CF3—(CF2)x—(CH2)y—CH3   (I)



 wherein x is an integer ranging from 1 to 8 and y is an integer ranging from 2 to 10,
b) a triglyceride which is miscible with the semifluorinated compound at 20° C.; and
c) an emulsifier.

公开(公告)号：US20230330276A1

公开(公告)日：2023-10-19

申请号：US18339124

申请日：2023-06-21

Applicant: Clarity Pharmaceuticals Limited

Inventor： Matthew John HARRIS ,  Sean LUMB

IPC: A61K51/04 ,  A61K9/08 ,  A61K49/10

CPC classification number: A61K51/0482 ,  A61K9/08 ,  A61K49/106 ,  A61K51/0497 ,  A61P35/00

Abstract: Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.

公开(公告)号：US11779661B2

公开(公告)日：2023-10-10

申请号：US16348572

申请日：2017-11-08

Applicant: The General Hospital Corporation

Inventor： David Sosnovik ,  Lee Josephson ,  Howard Chen

IPC: A61K49/00 ,  A61K47/61 ,  A61K51/04 ,  A61K47/69 ,  A61K49/10 ,  C07D221/12 ,  C07D417/06 ,  C07D413/06

CPC classification number: A61K49/0054 ,  A61K47/61 ,  A61K47/6929 ,  A61K49/0021 ,  A61K49/0032 ,  A61K49/0052 ,  A61K49/10 ,  A61K51/0491 ,  A61K51/0497 ,  C07D221/12 ,  C07D413/06 ,  C07D417/06

Abstract: The present disclosure provides nucleic acid binding nanoprobes having one or more fluorochromes and a polymer, where each of the fluorochromes is connected to the polymer, and methods of using the same.

公开(公告)号：US20230302161A1

公开(公告)日：2023-09-28

申请号：US18042806

申请日：2021-08-25

Applicant: BIOGRAPHENE INC. ,  SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION

Inventor： Byung Hee HONG ,  Young Jin JUNG ,  Jong Bo PARK

IPC: A61K49/18 ,  A61K49/10

CPC classification number: A61K49/1818 ,  A61K49/10

Abstract: Provided is a method for preparing a carbon-13-containing graphene quantum dot available as an MRI contrast medium, a carbon-13-containing graphene quantum dot prepared by the method, and an MRI contrast medium comprising the carbon-13 graphene quantum dot.

公开(公告)号：US11709216B2

公开(公告)日：2023-07-25

申请号：US16840050

申请日：2020-04-03

Applicant: The Regents of the University of California

Inventor： Peng Hu

IPC: G01R33/56 ,  A61B5/02 ,  A61N1/05 ,  A61K49/10 ,  A61B5/055 ,  A61B5/339 ,  G01R33/563

CPC classification number: G01R33/5602 ,  A61B5/02028 ,  A61B5/055 ,  A61B5/339 ,  A61K49/103 ,  A61K49/105 ,  A61N1/05 ,  G01R33/5601 ,  G01R33/5635 ,  G01R33/56325

Abstract: Disclosed herein are methods and systems for clinical practice of medical imaging on patients with metal-containing devices, such as implanted cardiac devices. In particular, Disclosed herein are methods and systems for improved late gadolinium enhancement (LGE) MRI for assessing myocardial viability for patients with implanted cardiac devices, i.e., cardiac pacemakers and implantable cardiac defibrillators.

公开(公告)号：US20230158177A1

公开(公告)日：2023-05-25

申请号：US18056349

申请日：2022-11-17

Applicant: Vikram Kodibagkar ,  Babak Moghadas

Inventor： Vikram Kodibagkar ,  Babak Moghadas

IPC: A61K49/10 ,  C07D233/91 ,  C07F15/02

CPC classification number: A61K49/106 ,  C07D233/91 ,  C07F15/025

Abstract: The present disclosure provides for a novel hypoxia-targeting contrast agent for noninvasive detection of hypoxia using magnetic resonance imaging. Also disclosed is a process of preparing the novel hypoxia-targeting contrast agent, as well as methods of using the novel hypoxia-targeting contrast agent.

公开(公告)号：US20230137434A1

公开(公告)日：2023-05-04

申请号：US17912312

申请日：2021-03-19

Applicant: Vascular Biosciences

Inventor： David Mann

IPC: A61K47/64 ,  A61K31/573 ,  A61P9/00 ,  A61P37/06 ,  A61P31/14 ,  A61K47/55 ,  A61K9/127 ,  A61P29/00 ,  A61K31/706 ,  A61K39/395 ,  A61K49/18 ,  A61K49/10 ,  A61K49/14 ,  A61P3/10 ,  A61K31/197 ,  A61K38/36 ,  A61K38/21 ,  A61K51/08 ,  A61K9/00 ,  A61K38/08

Abstract: A conjugate for treating an individual suffering from a disease, wherein the conjugate is comprised of: a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; and at least one therapeutic molecule and methods for making and administering same. Also disclosed is a combination product for use in the treatment of a disease, wherein the combination product comprises: (a) a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; (b) a liposome, wherein the targeting peptide is encapsulated within the liposome; and (c) an effective amount of an anti-inflammatory agent and methods for making and administering same.

公开(公告)号：US20230052140A1

公开(公告)日：2023-02-16

申请号：US17876272

申请日：2022-07-28

Applicant: Centre for Probe Development and Commercialization

Inventor： Eric Steven Burak ,  John Richard Forbes ,  Matthew David Burr Moran ,  Ryan Wayne Simms ,  John Fitzmaurice Valliant ,  Alla Darwish

IPC: A61K51/04 ,  A61P35/00 ,  A61K51/10 ,  C07K16/28 ,  A61K49/10 ,  C07K16/26

Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.